STOCK TITAN

Zomedica grants director 2.13M stock appreciation rights

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Zomedica Corp. (ZOMDF) director Jeffrey M. Rowe acquired 2,126,959 stock appreciation rights on November 16, 2026. The award covers 2,126,959 underlying common shares and has a $0.10 exercise price. The rights are exercisable on November 15, 2027, and expire November 15, 2036. Rowe’s reported direct position after the award was 2,126,959 rights.

Insider Rowe Jeffrey M
Role Director
Type Security Shares Price Value
Grant/Award Stock Appreciation Right 2,126,959 $0.00 $0.00
Holdings After Transaction: Stock Appreciation Right — 2,126,959 rights (Direct)
Holdings Before and After: Stock Appreciation Right, 0 to 2,126,959 rights (Direct)
Stock appreciation rights awarded 2,126,959 rights Acquired by director Jeffrey M. Rowe on November 16, 2026; reported direct position after the award was 2,126,959 rights.
Underlying common shares 2,126,959 shares Shares underlying the awarded stock appreciation rights.
Exercise price $0.10 per share Exercise price for the stock appreciation rights.
Exercise date November 15, 2027 Date the stock appreciation rights are exercisable.
Expiration date November 15, 2036 Expiration date of the stock appreciation rights.
Stock Appreciation Right technical
"grant of 2,126,959 stock appreciation rights"
A stock appreciation right (SAR) is a form of employee pay that gives the holder the right to receive the increase in a company's share price over a set reference price, paid in cash or shares, without having to buy stock first. It matters to investors because SARs can create future cash outflows or dilute existing shareholders if settled in stock, and they align employee incentives with share-price performance like a bonus tied to a home's price rise.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock appreciation rights did ZOMDF director Jeffrey M. Rowe receive?

Jeffrey M. Rowe acquired 2,126,959 stock appreciation rights on November 16, 2026. The award covers 2,126,959 underlying common shares.

What are the exercise terms for Jeffrey M. Rowe’s ZOMDF stock appreciation rights?

The rights have a $0.10 exercise price and are exercisable on November 15, 2027. They expire on November 15, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rowe Jeffrey M

(Last)(First)(Middle)
1101 TECHNOLOGY DRIVE
STE 100

(Street)
ANN ARBOR MICHIGAN 48108

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Zomedica Corp. [ ZOMDF ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Appreciation Right$0.111/16/2026A2,126,95911/15/202711/15/2036Common2,126,959$02,126,959D
Explanation of Responses:
/s/ Jeffrey Rowe11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading